Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2026)
Inhibikase Therapeutics' (IKT) quarterly EPS (Basic) came in at -$0.1 in Q1 2026, up 36.5% year-on-year from -$0.08 in Q1 2025, and up 52.6% on a QoQ basis from -$0.22 in Q4 2025.
Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of EPS (Basic) data on file, last reported at -$0.1 in Q1 2026.
- On a quarterly basis, EPS (Basic) rose 36.5% year-over-year to -$0.1 in Q1 2026; TTM through Mar 2026 was -$0.37, a 15.58% increase from a year earlier, with the FY2025 full-year figure at -$0.85, up 66.2% from the prior year.
- EPS (Basic) for Q1 2026 stood at -$0.1, up from -$0.22 in the prior quarter.
- Over the last five years, EPS (Basic) for IKT reached as high as -$0.1 in Q1 2026 and fell as low as -$1.19 in Q2 2023.
- Historically, EPS (Basic) has averaged -$0.69 across 5 years, with a median of -$0.76 in 2024.
- Across the five-year window, EPS (Basic) decreased 8.25% in 2023 and soared 82.64% in 2025, its largest moves.
- Year by year, EPS (Basic) stood at -$1.03 in 2022, then climbed by 19.96% to -$0.83 in 2023, then soared by 33.97% to -$0.55 in 2024, then surged by 59.94% to -$0.22 in 2025, then surged by 52.6% to -$0.1 in 2026.
- Per Business Quant data, the three most recent EPS (Basic) figures were -$0.1 in Q1 2026, -$0.22 in Q4 2025, and -$0.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Inhibikase Therapeutics | 407.51 Mn | 237.14 Mn | - | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.22 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.16 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.67 |
| Jun 30, 2024 | -0.70 |
| Mar 31, 2024 | -0.76 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.90 |
| Jun 30, 2023 | -1.19 |
| Mar 31, 2023 | -1.04 |
| Dec 31, 2022 | -1.03 |
| Sep 30, 2022 | -1.09 |
| Jun 30, 2022 | -1.10 |
| Mar 31, 2022 | -1.10 |
| Dec 31, 2021 | -1.66 |
| Sep 30, 2021 | -1.07 |
| Jun 30, 2021 | -1.29 |